4/18
01:00 am
eprx
Low
Report
4/13
09:28 am
eprx
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences [Canadian Business Journal (Canada)]
Low
Report
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences [Canadian Business Journal (Canada)]
4/13
08:00 am
eprx
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Low
Report
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
3/23
08:42 am
eprx
Eupraxia Pharmaceuticals (EPRX) is now covered by William Blair. They set an "outperform" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (EPRX) is now covered by William Blair. They set an "outperform" rating on the stock.
3/19
06:20 am
eprx
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
08:29 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
3/17
08:01 am
eprx
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
3/17
07:54 am
eprx
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:00 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Medium
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
3/12
09:03 pm
eprx
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Low
Report
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
2/21
02:04 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
2/20
03:50 pm
eprx
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
2/20
03:10 pm
eprx
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Low
Report
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
2/19
02:18 am
eprx
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
High
Report
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
2/18
04:01 pm
eprx
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Medium
Report
Eupraxia Pharmaceuticals Announces Proposed Public Offering